Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS

Go back to Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS

Mizuho Securities Remains Sidelined Following Endo Int'l's (ENDP) Mixed 4Q Results

March 2, 2016 7:10 AM EST

Mizuho Securities reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $42.00 (from $55.00), following the company's 4Q earnings report. ENDP reported revenues of $1.07B, in-line with consensus' estimate. EPS was reported at $1.36, ahead of expectations of $1.27. ENDP introduced... More

Piper Jaffray Remains Bullish on Endo Int'l (ENDP) Following an In-Line 4Q - PT to $81

March 1, 2016 9:04 AM EST

Piper Jaffray maintained an Overweight rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $81.00 (from $83.00), following the company's relatively in-line 4Q earnings results. Endo reported 4Q15 non-GAAP EPS of $1.36 on revenues of $1.1B. Sales of Xiaflex in 4Q15 were $50M, up 26% versus 3Q15 sales of $40M, with ENDP citing... More

Leerink Partners Cuts Price Target on Endo Int'l (ENDP) Following 4Q Earnings Report

March 1, 2016 7:50 AM EST

Leerink Partners maintained an Outperform rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $51.00 (from $64.00), following the company's 4Q earnings report. ENDP generics were unfavorably impacted by increased pricing pressure in pain and commodity products within legacy Qualitest, an... More